Streetbeat News

Analyst Ratings

INTA

Intapp (NASDAQ:INTA) has received varied analyst ratings, with most being bullish. Recent evaluations show an increase in average price targets, indicating positive sentiment. Intapp's financial performance includes a 20.88% revenue growth and a strong net margin, though its ROE is below industry averages.

Portfolio Pulse from Benzinga Insights

September 23, 2024 | 1:01 pm

DKNG

DraftKings (NASDAQ:DKNG) has received 32 analyst ratings over the past three months, with a majority being bullish. The average 12-month price target is $52.34, a slight decline from previous estimates. Analysts have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. DraftKings shows strong financial performance with significant revenue growth, high net margin, and effective debt management.

Portfolio Pulse from Benzinga Insights

September 23, 2024 | 1:00 pm

VST

Analysts have varied opinions on Vistra (NYSE:VST) with recent ratings showing a mix of bullish and somewhat bullish sentiments. The average 12-month price target has increased by 3.1% to $116.5. Analysts have raised their price targets, reflecting positive market conditions and company performance. Vistra's financials show strong revenue growth but challenges in profitability and debt management.

Portfolio Pulse from Benzinga Insights

September 23, 2024 | 1:00 pm

NAMS

NewAmsterdam Pharma (NASDAQ:NAMS) has received mixed analyst ratings over the past three months, with a majority being somewhat bullish. Analysts have set a 12-month price target range of $31.00 to $37.00, with an average of $33.75, slightly up from the previous $33.00. The company shows strong revenue growth but faces challenges in profitability and asset utilization.

Portfolio Pulse from Benzinga Insights

September 23, 2024 | 1:00 pm

HCI

JMP Securities analyst Matthew Carletti has reiterated a Market Outperform rating for HCI Group, maintaining a price target of $145.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 1:00 pm

KVUE

Kenvue (NYSE:KVUE), the world's largest pure-play consumer health company, has received diverse analyst ratings ranging from bullish to indifferent. Recent analyst actions include raising and lowering price targets, with an average 12-month target of $22.5. Despite a slight revenue decline, Kenvue shows strong financial health with high net margins and ROE.

Portfolio Pulse from Benzinga Insights

September 23, 2024 | 1:00 pm

TRUP

Stifel analyst Jonathan Block maintains a Hold rating on Trupanion (NASDAQ:TRUP) and raises the price target from $30 to $40.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 12:58 pm

CNM

Wells Fargo has initiated coverage on Core & Main (NYSE:CNM) with an Overweight rating and set a price target of $52.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 12:58 pm

IRM

Stifel analyst Shlomo Rosenbaum has maintained a Buy rating on Iron Mountain (NYSE:IRM) and raised the price target from $117 to $140.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 12:56 pm

SY

Citigroup has downgraded So-Young Intl from Buy to Neutral and reduced its price target from $1.5 to $0.8, indicating a less optimistic outlook for the company.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 12:55 pm